Capecitabine
Capecitabine has been studied in 6 papers since 2017: 2 trials and 1 observational study in people, 1 in animals, 1 in cells, 1 review. It is an approved medicine. The newest paper, Jan 17, 2025: “Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations”.
See all 11 papers on capecitabine
At a glance
The findings reach people, from one lab or study. 3 independent labs in 3 countries; 1,478 trials, 1 about aging, 458 with no results posted.
“In colon cancer, capecitabine and irinotecan was associated with higher cognitive im-pairment”
None of its findings points the other way.
- 3 independent labs in 3 countries
- 1,478 trials, 1 about aging, 458 with no results posted
- Funders: Georgia Institute of Technology and 5 more
- Human trial2
- Humans1
- Model organisms1
- Cells1
What did studies of capecitabine find?
2Studies of capecitabine measured 2 outcomes: lifespan and CD146.
Lifespan
upin Rotifera1
1 study
Lifespan
upin Rotifera1
Capecitabine extends lifespan in Rotifera.
“Exposures to 1 μM erythromycin, 5 μM carglumic acid, 3 μM capecitabine, and 1 μM ivermectin, extended rotifer lifespan without significant effect on reproduction.”
Model organisms3 μM
Biogerontology
CD146
upin humans1
1 study
CD146
upin humans1
Capecitabine is linked with higher CD146 in patients after versus before capecitabine chemotherapy.
“sVCAM-1 and CD146 concentrations were higher after than before capecitabine chemotherapy.”
Humansin patients after versus before capecitabine chemotherapy
British journal of pharmacology
What is capecitabine linked with?
1Studies link capecitabine with cognitive impairment.
Cognitive impairment
upin humans1
1 study
Cognitive impairment
upin humans1
Capecitabine is linked with a higher risk of cognitive impairment in humans (colon cancer).
“In colon cancer, capecitabine and irinotecan was associated with higher cognitive im-pairment”
Humanscolon cancer
Preprints.orgPreprint
Has capecitabine been tested in people?
1 of 1,478 about agingYes: 2 trials and 1 observational study in people have been published, and 1,478 trials are registered.
About aging
Phase 4Status unknown
Approved
Apr 30, 1998DiscontinuedAdvanced or Metastatic Breast Cancer, Breast Cancer, Colorectal Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Cancer, Locally Advanced Rectal Cancer, Metastatic Colorectal Cancer, Pancreatic Adenocarcinoma, Pancreatic Cancer, Stage III Colon Cancer
Feb 2, 2001Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms, Advanced Gastric Cancer, Locally Advanced or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Stage III Colon Cancer
Apr 20, 2012Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms, Advanced Gastric Cancer, Locally Advanced or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Stage III Colon Cancer
Apr 20, 2012Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms, Advanced Gastric Cancer, Locally Advanced or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Colon Cancer, Stage III Colon Cancer
EMA Ecansya (previously Capecitabine Krka)
Apr 20, 2012Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms, Advanced Gastric Cancer, Locally Advanced or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Colon Cancer, Stage III Colon Cancer
Nov 19, 2012Colorectal Neoplasms, Advanced Gastric Cancer, Locally Advanced or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Colon Cancer, Stage III Colon Cancer
All 7Fewer
Repurposing
Phase 3Results posted68 trials
Phase 4Recruiting15 trials
Pancreatic ductal adenocarcinoma
Phase 4Status unknown4 trials
Phase 4Status unknown1 trial
Phase 3Status unknown1 trial
Esophageal squamous cell carcinoma
Phase 3Recruiting14 trials
40 of 112Fewer
Every condition in trials
Adenocarcinoma of the Stomach
Phase 4Terminated2 trials
HER 2 Positive Gastric Cancer
Phase 4Status unknown2 trials
Locally Advanced Colorectal Cancer
Phase 4Status unknown2 trials
Gastric gastroesophageal junction adenocarcinoma
Phase 4Status unknown1 trial
Triple negative breast neoplasm
Phase 3Completed37 trials
Biliary tract neoplasm
Phase 3Status unknown24 trials
40 of 84Fewer
Readouts due
- Nov 2026
- Nov 30, 2026
- Dec 2026
- Dec 2026
- Dec 2026
- Dec 31, 2026
All 36Fewer
Stopped
NCT00216424TerminatedColorectal neoplasm
lack of accrual
NCT07057089SuspendedLocally advanced rectal cancer
Suspended due to lack of drug supply: the manufacturer ceased to provide investigational drug supply.
NCT00871273TerminatedAdenocarcinoma of the Stomach
1\. Slow recruitment; 2. Change to clinical environment reducing the pool of potentially eligible patients; 3. Availability of data from another similar study
NCT00440622TerminatedTumor
Due to poor accrual
NCT05134194TerminatedTriple negative breast neoplasm
Sponsor R \& D Strategy Adjustment\]
NCT00345059TerminatedAdvanced non small cell lung cancer
slow accrual
All 33Fewer
Who is developing capecitabine?
3 companies: Akeso, Processa Pharmaceuticals and Pfizer.
Trial sponsors
Company67 trialsPhase 420,723 people
Company11 trialsPhase 41,710 people
Company10 trialsPhase 45,374 people
Company3 trialsPhase 4473 people
Company1 trialPhase 485 people
Company8 trialsPhase 32,615 people
Company7 trialsPhase 34,016 people
Company7 trialsPhase 32,082 people